These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24721290)

  • 1. Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice.
    Lafuente-Urrez RF; Pérez-Pelegay J
    Eur J Dermatol; 2014; 24(2):217-23. PubMed ID: 24721290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
    Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
    J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
    J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.
    van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
    López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
    Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
    Navarini AA; Poulin Y; Menter A; Gu Y; Teixeira HD
    J Drugs Dermatol; 2014 May; 13(5):554-62. PubMed ID: 24809878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.
    Bardazzi F; Balestri R; Baldi E; Antonucci A; De Tommaso S; Patrizi A
    Dermatol Ther; 2010; 23 Suppl 1():S14-9. PubMed ID: 20136916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
    Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1298-303. PubMed ID: 21967627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R; Unnebrink K; Valdecantos WC
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
    Papp K; Menter A; Poulin Y; Gu Y; Sasso EH
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.